Inhibitors of the Maillard Reaction and AGE Breakers as Therapeutics for Multiple Diseases
The Maillard reaction is a complex series of reactions that involve reducing-sugars and proteins, giving a multitude of end-products that are known as advanced glycation end-products (AGEs). AGEs can contribute to the pathogenesis of diabetes and neurological diseases such as Alzheimer's disease. AGEs also play a major role in vascular stiffening, atherosclerosis, osteoarthritis, inflammatory arthritis and cataracts. Thus, AGE inhibitors and AGE breakers offer a potential strategy as therapeutics for diverse diseases. Various AGE inhibitors have been developed in recent years, and their underlying mechanism is based on the attenuation of glycoxidation and/or oxidative stress by the sequestration of metal ions, reactive 1,2-dicarbonyl compounds, and reactive oxygen and reactive nitrogen species.
P. Reddy and A. Beyaz, "Inhibitors of the Maillard Reaction and AGE Breakers as Therapeutics for Multiple Diseases," Drug Discovery Today, vol. 11, no. 13-14, pp. 646-654, Elsevier, Jul 2006.
The definitive version is available at https://doi.org/10.1016/j.drudis.2006.05.016
Keywords and Phrases
2 isopropylidenehydrazono 4 oxo 5 thiazolidinylacetanilide; 4 oxo n phenyl 4,5 dihydro 2 [(1 methylethylidene)hydrazino] 5 thiazoleacetamide; acetamide derivative; acetylsalicylic acid; advanced glycation end product; advanced glycation end product breaker; advanced glycation end product inhibitor; advanced glycation end product receptor; alagebrium; alt 946; aminoguanidine; angiotensin receptor antagonist; antioxidant; blocking agent; bromine derivative; can c; carnosine; clioquinol; deferoxamine; dipeptidyl carboxypeptidase inhibitor; homocarnosine; iron chelating agent; metformin; n [[2 (hydrazinoiminomethyl)amino]ethyl]acetamide; n acetylcarnosine; n acetylcarnosine; n phenacyl 1,3 thiazolium bromide; nifedipine; perindopril; prodrug; pyridorin; pyridoxamine; soluble advanced glycation end product receptor; tenilsetam; thiazole derivative; unclassified drug; Alzheimer disease; arthritis; atherogenesis; atherosclerosis; cataract; cataractogenesis; chemoprophylaxis; clinical trial; diabetes mellitus; diabetic nephropathy; diabetogenesis; drug mechanism; glycation; human; hypertension; inflammation; neurologic disease; neuroprotection; nonhuman; osteoarthritis; oxidation; oxidative stress; Parkinson disease; pathogenesis; pyridoxine deficiency; reduction; review; rigidity; vascular disease; Aging; Animals; Diabetes Mellitus, Type 2; Glycosylation End Products, Advanced; Guanidines; Humans; Hypoglycemic Agents; Maillard Reaction; Metformin; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Reactive Oxygen Species; Receptors, Immunologic; Alzheimer's disease; Diabetes; Maillard reaction
International Standard Serial Number (ISSN)
Article - Journal
© 2006 Elsevier, All rights reserved.
01 Jul 2006